XASX
4DX
Market cap73mUSD
Jul 03, Last price
0.24AUD
1D
-2.04%
1Q
-4.00%
IPO
-38.46%
Name
4DMedical Ltd
Chart & Performance
P/E
—
P/S
29.76
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.59%
Rev. gr., 5y
40.12%
Revenues
4m
+1,230.44%
Net income
-36m
L+14.36%
CFO
-31m
L+36.26%
Earnings
Aug 28, 2025
Profile
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2015‑12 | |
| Income | |||||||||
Revenues | 3,754 1,230.44% | 282 -73.24% | |||||||
Cost of revenue | 31,098 | 29,182 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (27,344) | (28,900) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (4,417) | 323 | |||||||
Tax Rate | |||||||||
NOPAT | (22,927) | (29,224) | |||||||
Net income | (35,979) 14.36% | (31,460) 27.92% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 35,000 | 42,558 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 945 | 933 | |||||||
Long-term debt | 9,297 | 9,344 | |||||||
Deferred revenue | 718 | ||||||||
Other long-term liabilities | 15,240 | 186 | |||||||
Net debt | (20,365) | (59,344) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (30,867) | (22,653) | |||||||
CAPEX | (156) | (731) | |||||||
Cash from investing activities | (40,040) | (1,614) | |||||||
Cash from financing activities | 31,937 | 42,728 | |||||||
FCF | (22,416) | (28,130) | |||||||
| Balance | |||||||||
Cash | 30,606 | 69,576 | |||||||
Long term investments | 45 | ||||||||
Excess cash | 30,418 | 69,607 | |||||||
Stockholders' equity | 70,927 | 71,460 | |||||||
Invested Capital | 61,588 | 7,178 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 327,079 | 300,014 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (23,279) | (26,335) | |||||||
EV/EBITDA | |||||||||
Interest | 264 | 7 | |||||||
Interest/NOPBT | |||||||||